Profit before interest, taxes, depreciation and amortization ^
DGAP-News: Biotest AG / Keywords: Semi-annual results
Biotest AG: Biotest increases EBITDA by 52% to EUR 8.8 million in the first half of the year
27/07/2022 / 08:30
The best jobs of the day
Find the best job offers now and
be notified by e-mail.
The issuer / publisher is responsible for the content of the application.
————————————————– —————————————
PRESS RELEASE
Biotest increases EBITDA by 52% to EUR 8.8 million in the first half of the year
* In a difficult environment, Biotest almost achieved sales from the previous year
* Opening of 4 plasma collection points in the first half of the year
* More plasma centers planned for 2022
Dreieich, July 28, 2022 In the first half of the fiscal year 2022
The Biotest Group achieved sales of EUR 253.1 million. This is data
difficult global economic situation, the pandemic of the crown and
difficult supply of human plasma more than satisfactory. FROM
year-on-year decrease by EUR 257.8 million
1.8%.
Profit before interest, taxation, depreciation (EBITDA) was
In the first half of the financial year 2022 to EUR 8.8 million, EUR 5.8 million in the first
six months of the previous year. This corresponds to an increase of 51.7%.
EBIT in the first half of 2022 amounted to EUR 9.1 million and thus amounted to
below last year’s value – EUR 8.5 million. This year they are in it
Expenditure on the Biotest Next Level project in the amount of EUR 41.5 million
of which (previous year: EUR 38.0 million).
It is characterized by a global increase in the demand for immunoglobulins
while the pandemic was still severe, Biotest was able to:
the adjusted pricing policy will in particular increase the sales of Intratec®.
This development, however, may reduce sales in the rest
product areas do not fully balance each other.
During the reporting period, Biotest AG was already able to open a fourth one
are implementing new plasma collection centers. Moreover, other new ones
planned plasma centers in 2022 to increase plasma supply to
providing a broader base.
Full data will be available for the first half of fiscal year 2022
Publish Biotest on August 11, 2022.
About Biotest
Biotest is a supplier of plasma proteins and biotherapeutics
anxieties. With a value chain that stretches from preclinical research and
from clinical development to global marketing
Biotest primarily in the areas of clinical immunology applications,
He specializes in hematology, intensive care and emergency medicine. biotest
develops and sells immunoglobulins, coagulation factors and albumin,
which are produced on the basis of human blood plasma and
Diseases of the immune system or the hematopoietic system are used
come on. Biotest employs over 2,000 people worldwide. stalk
and the preferred shares of Biotest AG are in the Prime Standard of the German Stock Exchange
listed.
IR contact:
Dr. Monica Buttkereit
Phone: + 49-6103-801-4406
E-mail: [email protected]
PR contact:
Dirk Neumuller
Telephone: +49 -6103-801-269
E-mail: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com
Ordinary action: WKN: 522720; ISIN: DE0005227201
Preferred share: WKN: 522723; ISIN: DE0005227235
Listed: Frankfurt (highest standard)
Open Market: Berlin, Düsseldorf, Hamburg / Hanover, Munich, Stuttgart,
Tradegate
Reservation
This document contains forward-looking statements regarding:
general economic development, as well as business, profit and financial development
financial standing of Biotest AG and its subsidiaries. This
Statements are based on current plans, estimates, forecasts and
the expectations of the firm and are therefore at risk and
Uncertainty factors that may lead to the actual
significantly deviates from the expected development. Looking to the future
Statements are only valid at the time of publication. biotest
does not intend to update any forward-looking statements i
bears no obligation for this.
————————————————– —————————————
07/28/2022 publication of corporate news / financial announcement,
provided by DGAP – EQS Group AG service.
The issuer / publisher is responsible for the content of the application.
DGAP’s distribution services include statutory reporting requirements,
Corporate / financial news and press releases.
Media archive at http://www.dgap.de
————————————————– —————————————
German
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 – 8 01-0
Fax: 0 61 03 – 8 01-150
E-mail: [email protected]
Internet: www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Exchanges: Regulated market in Frankfurt (Prime Standard);
Open market in Berlin, Dusseldorf, Hamburg, Hannover,
Munich, Stuttgart, Tradegate Exchange
EQS message ID: 1406293
End of news DGAP news service
————————————————– —————————————
1406293 28/07/2022
°